Intuitive Surgical (ISRG) stock has fallen 13.5% in the last three months despite strong procedure growth and adoption of its da Vinci 5 system. The company’s fundamentals, including projected 13-15% global da Vinci procedure growth in 2026 and expansion into new surgical categories, suggest a constructive investment stance. While facing margin headwinds and competitive pressures, ISRG’s market leadership and recurring revenue base position it for continued value creation, leading to a Zacks Rank #1 (Strong Buy).
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
Should You Buy ISRG Stock Despite a 13% Fall in Three Months?
Intuitive Surgical (ISRG) stock has fallen 13.5% in the last three months despite strong procedure growth and adoption of its da Vinci 5 system. The company’s fundamentals, including projected 13-15% global da Vinci procedure growth in 2026 and expansion into new surgical categories, suggest a constructive investment stance. While facing margin headwinds and competitive pressures, ISRG’s market leadership and recurring revenue base position it for continued value creation, leading to a Zacks Rank #1 (Strong Buy).